Association of serum irisin with metabolic syndrome in obese Chinese adults
- PMID: 24709991
- PMCID: PMC3978033
- DOI: 10.1371/journal.pone.0094235
Association of serum irisin with metabolic syndrome in obese Chinese adults
Abstract
Irisin, a recently identified novel myokine, drives brown-fat-like conversion of white adipose tissues and has been proposed to mediate beneficial effects of exercise on metabolism. Circulating irisin was significantly reduced in type 2 diabetes patients; however, no evidence is available about its association with metabolic syndrome (MetS) and effects of adiposity and muscle mass on circulating irisin have been controversial. Cross-sectional data on socio-demographic, lifestyle, clinical characteristics and serum irisin were collected for 1,115 community-living Chinese adults with central obesity. Associations of serum irisin with MetS (central obesity plus any two of the following four factors (raised blood pressure (BP), raised fasting plasma glucose (FPG), raised triglyceride (TG), and reduced HDL cholesterol) and each component of MetS were analyzed using multivariable logistic regression. Among the 1,115 obese Chinese adults with a mean age of 53.2(±7.2) years, serum irisin levels (log-transformed) were significantly reduced in subjects with MetS and raised FPG than their control groups (p = 0.034 and 0.041, respectively). After adjustment for potential confounders, serum irisin was significantly associated with reduced risks of MetS and raised FPG, with odds ratios (ORs) (95% CI) per standard deviation of log-transformed irisin of 0.796 (0.505-0.959, p = 0.027) and 0.873 (0.764-0.998, p = 0.046), respectively. Associations of irisin with raised BP, raised TG and reduced HDL were not statistically significant ((ORs) (95% CI): 0.733(0.454-1.182, p = 0.202), 0.954(0.838-1.086, p = 0.478) and 1.130(0.980-1.302, p = 0.092), respectively). Stepwise multivariable linear regression analysis showed that fasting insulin, HbA1c and albumin/globulin ratio were negatively associated with serum irisin level with statistical significance (all p-values <0.05) and waist circumference was negatively associated with serum risin with marginally statistical significance (p = 0.055). These results imply that irisin may play an important role in insulin resistance and MetS and should be confirmed in future prospective studies.
Conflict of interest statement
Similar articles
-
Association of serum irisin and body composition with chronic kidney disease in obese Chinese adults: a cross-sectional study.BMC Nephrol. 2015 Feb 11;16:16. doi: 10.1186/s12882-015-0009-5. BMC Nephrol. 2015. PMID: 25884312 Free PMC article.
-
Circulating irisin in relation to insulin resistance and the metabolic syndrome.J Clin Endocrinol Metab. 2013 Dec;98(12):4899-907. doi: 10.1210/jc.2013-2373. Epub 2013 Sep 20. J Clin Endocrinol Metab. 2013. PMID: 24057291 Free PMC article.
-
Increased irisin versus reduced fibroblast growth factor1 (FGF1) in relation to adiposity, atherogenicity and hematological indices in metabolic syndrome patients with and without prediabetes.Horm Mol Biol Clin Investig. 2019 Mar 6;38(1). doi: 10.1515/hmbci-2018-0063. Horm Mol Biol Clin Investig. 2019. PMID: 30840586
-
Irisin reduces inflammatory signaling pathways in inflammation-mediated metabolic syndrome.Mol Cell Endocrinol. 2022 Jul 15;552:111676. doi: 10.1016/j.mce.2022.111676. Epub 2022 May 13. Mol Cell Endocrinol. 2022. PMID: 35569582 Free PMC article. Review.
-
The therapeutic potential of irisin to mitigate the risk of metabolic syndrome in postmenopausal women.Front Reprod Health. 2024 Jul 8;6:1355922. doi: 10.3389/frph.2024.1355922. eCollection 2024. Front Reprod Health. 2024. PMID: 39040132 Free PMC article. Review.
Cited by
-
Effects of Body Weight Reduction on Serum Irisin and Metabolic Parameters in Obese Subjects.Diabetes Metab J. 2016 Oct;40(5):386-395. doi: 10.4093/dmj.2016.40.5.386. Epub 2016 Sep 27. Diabetes Metab J. 2016. PMID: 27766246 Free PMC article.
-
Irisin Inhibits Hepatic Cholesterol Synthesis via AMPK-SREBP2 Signaling.EBioMedicine. 2016 Apr;6:139-148. doi: 10.1016/j.ebiom.2016.02.041. Epub 2016 Feb 27. EBioMedicine. 2016. PMID: 27211556 Free PMC article.
-
Superiority of the Non-Glycosylated Form Over the Glycosylated Form of Irisin in the Attenuation of Adipocytic Meta-Inflammation: A Potential Factor in the Fight Against Insulin Resistance.Biomolecules. 2019 Aug 21;9(9):394. doi: 10.3390/biom9090394. Biomolecules. 2019. PMID: 31438646 Free PMC article.
-
A Review on the Role of Irisin in Insulin Resistance and Type 2 Diabetes Mellitus.J Pharmacopuncture. 2017 Dec;20(4):235-242. doi: 10.3831/KPI.2017.20.029. Epub 2017 Oct 10. J Pharmacopuncture. 2017. Retraction in: J Pharmacopuncture. 2020 Mar 31;23(1):42-43. doi: 10.3831/KPI.2020.23.007. PMID: 30151293 Free PMC article. Retracted.
-
The Effect of n-3 Polyunsaturated Fatty Acids Supplementation on Serum Irisin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.Int J Endocrinol Metab. 2017 Jan 21;15(1):e40614. doi: 10.5812/ijem.40614. eCollection 2017 Jan. Int J Endocrinol Metab. 2017. PMID: 28835761 Free PMC article.
References
-
- Eckel RH, Alberti KG, Grundy SM, Zimmet PZ (2010) The metabolic syndrome. Lancet 375: 181–183. - PubMed
-
- Lakka HM, Laaksonen DE, Lakka TA, Nishanen LK, Kumpusalo E, et al. (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: 2709–2716. - PubMed
-
- Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, et al. (2004) Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in the United States adults. Circulation 110: 1245–1250. - PubMed
-
- Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343–1350. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous